Gene therapy in heart disease.
As the technology for gene therapy develops in vitro and in vivo in animal models, it is becoming clear that the three principal approaches--recombinant retroviruses, recombinant adenovirus, and direct DNA delivery--will ultimately have applications in specific therapeutic situations that take full advantage of the unique features of the specific delivery system: low level persistent expression after ex vivo recombinant retroviral therapy, high level transient expression after in vivo recombinant adenoviral therapy, or moderate level transient expression after in vivo administration of a synthetic DNA complex, which in principle could be repeated as desired.
Smith
L C
LC
Department of Cell Biology, Howard Hughes Medical Institute, Baylor College of Medicine, Houston, TX 77030-3498, USA.
Eisensmith
R C
RC
Woo
S L
SL
D000818:Animals; D001693:Biological Transport, Active; D004274:DNA, Recombinant / Q000008:administration & dosage / Q000235:genetics; D011992:Endosomes / Q000378:metabolism; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D006331:Heart Diseases / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D066298:In Vitro Techniques; D009975:Orthomyxoviridae / Q000235:genetics; D011973:Receptors, LDL / Q000172:deficiency / Q000235:genetics
D004274:DNA, Recombinant; D011973:Receptors, LDL